XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Trade Receivables
 12 Months Ended
Dec. 31, 2022
Receivables [Abstract]  
Trade Receivables Trade Receivables
Product Sales
Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO® and RAPIVAB®. At December 31, 2022 and 2021, receivables related to sales of ORLADEYO were $41,508 and $27,384, respectively. At December 31, 2022 and 2021, receivables related to sales of RAPIVAB were $823 and $49, respectively. No bad debt reserve or allowance amounts were recorded as of December 31, 2022 and December 31, 2021, respectively.
Collaborations
Receivables from collaborations were as follows (in thousands):
 December 31, 2022
 BilledUnbilled Total
U.S. Department of Health and Human Services, net$7,218 $284 $7,502 
Royalty receivables from partners741 — 741 
Other collaborations— 25 25 
Total receivables from collaborators$7,959 $309 $8,268 
 December 31, 2021
 BilledUnbilledTotal
U.S. Department of Health and Human Services, net$5 $1,670 $1,675 
Royalty receivables from partners305 — 305 
Total receivables from collaborators$310 $1,670 $1,980 
As of December 31, 2022 and 2021, the Company maintained a reserve of $437 and $701, respectively, related to royalties associated with Green Cross.